Literature DB >> 8703855

Activated protein C resistance in young adults with central retinal vein occlusion.

J Larsson1, E Olafsdottir, B Bauer.   

Abstract

BACKGROUND: Central retinal vein occlusion is a disease that is most common in old people. While the disease in old people often is associated with atherosclerosis, hypertension, diabetes, or glaucoma, this is much less evident in young people. However, a new defect in the anticoagulant system has recently been discovered, activated protein C resistance. This hereditary defect may well be associated with central retinal vein occlusion, and so this factor was analysed in patients younger than 50 years with a history of central retinal vein occlusion.
METHODS: Blood samples were obtained from 31 patients younger than 50 years with a history of central retinal vein occlusion, and analysed for activated protein C resistance with standard clinical laboratory methods.
RESULTS: In this material 26% of all the patients and 36% of the patients younger than 45 years were resistant to activated protein C. The normal incidence of activated protein C resistance is 2-7%.
CONCLUSION: Activated protein C resistance seems to be the most common known cause of central retinal vein occlusion in young people.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703855      PMCID: PMC505428          DOI: 10.1136/bjo.80.3.200

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  [A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis].

Authors:  B Dahlbäck; P J Svensson
Journal:  Lakartidningen       Date:  1994-01-05

2.  Activated protein C resistance caused by Arg506Gln mutation in factor Va.

Authors:  J S Greengard; X Sun; X Xu; J A Fernandez; J H Griffin; B Evatt
Journal:  Lancet       Date:  1994-05-28       Impact factor: 79.321

3.  Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C.

Authors:  B Lindblad; P J Svensson; B Dahlbäck
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

4.  Activated protein C resistance in deep-vein thrombosis.

Authors:  C Legnani; G Palareti; R Biagi; S Coccheri
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

5.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

6.  Systemic factors contributory to retinal vein occlusion.

Authors:  M A McGrath; F Wechsler; A B Hunyor; R Penny
Journal:  Arch Intern Med       Date:  1978-02

7.  Resistance to activated protein C as a basis for venous thrombosis.

Authors:  P J Svensson; B Dahlbäck
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

8.  Long-term follow-up of occlusion of the central retinal vein in young adults.

Authors:  I A Priluck; D M Robertson; R W Hollenhorst
Journal:  Am J Ophthalmol       Date:  1980-08       Impact factor: 5.258

Review 9.  Central retinal vein occlusion in young adults.

Authors:  A C Fong; H Schatz
Journal:  Surv Ophthalmol       Date:  1993 May-Jun       Impact factor: 6.048

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more
  20 in total

Review 1.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  [Thrombophilic and systemic risk factors in patients with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; W Miesbach; I Scharrer; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

Review 4.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

5.  Activated protein C resistance in central retinal vein occlusion.

Authors:  G Sanborn
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

6.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

7.  Activated protein C resistance in patients with central retinal vein occlusion.

Authors:  J Larsson; A Sellman; B Bauer
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

8.  Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality.

Authors:  Jane Zea-Chin Kuo; Chi-Chun Lai; Frank Shih-Chang Ong; Chia-Pang Shih; Ling Yeung; Tun-Lu Chen; Kuan-Jen Chen; Wei-Chi Wu
Journal:  Retina       Date:  2010-03       Impact factor: 4.256

Review 9.  [Retinal vein occlusions].

Authors:  S Dithmar; L L Hansen; F G Holz
Journal:  Ophthalmologe       Date:  2003-07       Impact factor: 1.059

10.  Central retinal vein occlusion with therapeutic level of anticoagulation.

Authors:  Sarwat Salim; Wai-Ching Lam; Wahid Hanna
Journal:  Case Rep Med       Date:  2009-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.